Skip to content

Orange Book Blog

At the intersection of Patent and FDA Law

    • About
    • Authors
    • Disclaimer
    • Subscribe
  • Subscribe

Recent Posts

  • Revisiting Teva v. Lilly
  • Federal Circuit reiterates a bond is required for preliminary injunctions of generic launches
  • Hikma v. Amarin: Opinion Analysis
  • A note on ANDA settlement agreements
  • Hikma v. Amarin: Oral Argument Recap

  • Twitter
  • Facebook
  • Instagram

Follow-on Biologics News

April 17, 2007

A number of interesting news reports concerning follow-on biologics have been published in recent days:

  • “Hopes for Speedy Action on Generic Biologics Fade in Senate“–Biologic Drug Report 4/16/07
  • “Lobbyists Take Aim at Generic Biologics“–Boston Globe 4/16/07
  • “Senate HELP Panel to Review Comprehensive FDA Measure“–BioWorld Today 4/16/07
  • “Eyeing a Lucrative Drug Market“–NJBiz.com 4/16/07
  • “Biologics Legislation Will Speed Progress“–American Enterprise Institute 4/16/07
  • “Sen. Clinton’s Support for Generic Biotech Drug Legislation Could Deter Republicans, Lobbyists Say“–KaiserNetwork.org 4/13/07
  • “CCPM Applauds Letter from Bipartisan Group of Governors Urging Congressional Action on Biogenerics“–Yahoo! News 4/13/07

Share this:

  • Share on X (Opens in new window) X
  • Share on Facebook (Opens in new window) Facebook
Like Loading…
Posted in Biosimilars

Leave a comment Cancel reply

←Warner Chilcott Settles Antitrust Suits Brought by States and Indirect Purchasers Concerning Ovcon 35
FDA Refuses to Approve Any ANDAs for Generic Norvasc Besides Mylan’s–For Now→

Blog at WordPress.com.

  • Comment
  • Reblog
  • Subscribe Subscribed
    • Orange Book Blog
    • Already have a WordPress.com account? Log in now.
    • Orange Book Blog
    • Subscribe Subscribed
    • Sign up
    • Log in
    • Copy shortlink
    • Report this content
    • View post in Reader
    • Manage subscriptions
    • Collapse this bar
%d